Urogen Pharma (URGN) closed the last trading session at $12.70, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $39.36 indicates a 209.9% upside potential.The average comprises seven short-term price targets ranging from a low of $18 to a high of $64, with a standard deviation of $15.76. While the lowest estimate indicates an increase of 41.7% from the current price le ...

Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share releva ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript November 6, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO David Lin - CCO Chris Degnan - CFO Conference Call Participants Tara Bancroft - TD Cowen Ram Selvaraju - H. C. Wainwright & Co. Leland Gershel - Oppenheimer Kelsey Goodwin - Guggenheim Matt Kaplan - Ladenburg Thalmann Operator Good morning, ladies and gentlemen. Thank you for standing by and welcome to the UroGe ...

Urogen Pharma (URGN) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 34.52%. A quarter ago, it was expected that this company would post a loss of $0.82 per share when it actually produced a loss of $0.91, delivering a surprise of -10.98%.Over the last four quarters, the company has surpassed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 Israel 98-1460746 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4 ...

Exhibit 99.1 UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 • New Drug Application for UGN-102 accepted by US FDA; PDUFA target action date set for June 13, 2025 • JELMYTO® achieved net product sales of $25.2 million in Q3 2024, compared to $20.9 million in Q3 2023 • $254.2 million in cash, cash equivalents and marketable securities as of September 30, 2024 • Conference call and webcast to be held today at 10:00 AM ET PRI ...

13 August 2024 | 4:05PM EDT UroGen Pharma (URGN): 2024 Recap: Jelmyto sales flat; operating expenses edge higher ahead of NDA completion Jelmyto sales flat y/y as focus remains on completing the rolling NDA submission for UGN-102. URGN reported its 2Q24 results with topline sales of Jelmyto coming in at $21.8mn, in-line with our estimates of $22mn but below Visible Alpha Consensus Data of $23.5mn. The company said its commercial asset faced some headwinds related to 340B and other Medicaid/Medicare discount ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head, Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Dong Kim - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Raghuram Selvaraju - H.C. Wainwright & Co. Leland Gershell - Oppenheimer Kelsey Goodwin - Guggenheim Securities Matt Kaplan - Ladenburg Thalmann Pa ...

Urogen Pharma (URGN) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.03 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -10.98%. A quarter ago, it was expected that this company would post a loss of $0.93 per share when it actually produced a loss of $0.97, delivering a surprise of -4.30%. Over the last four quarters, the company has surpasse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 Israel 98-1460746 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 400 Al ...